$PSNL

Chen Richard sold $1.5M of PSNL

Chen Richard (President and CMO) sold 100,000 shares of Personalis, Inc. (PSNL) at $15.15 ($1.52M total) on 2026-07-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chen Richard
Published Jul 16, 2026, 1:27 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PSNL
Neutral
high confidence
Mentioned
$PSNL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PSNLNeutralLow
01

Why it matters

The disclosed sale provides a datapoint on insider behavior but does not, by itself, change the company’s disclosed fundamentals or guidance.

02

Market read

For PSNL traders, the main takeaway is insider selling magnitude ($1.515M) with 10b5-1 context, which typically reduces interpretive weight.

03

What to watch

Traders may want to compare with prior insider transactions and total insider ownership changes to judge whether this is part of a broader selling trend.

Relevance 5/10Novelty 5/10Timing: immediately following the 2026-07-15 insider sale disclosure on SEC EDGAR

Background

The article is an SEC Form 4 insider transaction for Personalis, Inc. (PSNL) filed on 2026-07-15, reporting a scheduled open-market sale by the company’s President and CMO.

Company-level read

Ticker impact

$PSNLNeutralHigh confidence
Context

Personalis insider Chen Richard (President and CMO) sold 100,000 shares on 2026-07-15 under a 10b5-1 plan, worth $1.515M.

Expected impact

Likely minimal, unless accompanied by other negative disclosures or unusual selling patterns.

Evidence & confidence

The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement; the article provides no new operating, regulatory, or financial datapoints beyond the sale details.

Market effects

No sector-level implications; this is company-specific insider trading disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled liquidity needs rather than bearish expectations.

Key entities

  • Personalis, Inc.

    US-listed company whose insider transaction is disclosed on SEC Form 4.

  • Chen Richard

    President and CMO who sold 100,000 shares under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

$PSNLMed

Personalis (PSNL) Has Investors Asking A Fresh Question

Personalis (PSNL) received a new $18.3M task order from the U.S. Department of Veterans Affairs, bringing its cumulative VA MVP task orders to $243.3M. The stock has seen significant gains, with a 30-day return of 42.57% and a year-to-date gain of 117.58%. Analysts estimate a fair value of $15.44 per share, suggesting the stock is overvalued at its last close of $17.08. Investors should consider risks such as delayed reimbursements and potential underperformance of large contracts.

$PSNLHighAI 8/10

Personalis Stock Jumps As Tempus AI Acquisition Reshapes Outlook

Personalis Inc. (PSNL) stock rose 9.41% after reporting Q2 revenue of $22.4M, exceeding consensus estimates. The company agreed to be acquired by Tempus AI for $16.25 per share. Clinical volume for its NeXT Personal MRD test surged 199% year over year, with guidance for over 500% clinical revenue growth in 2026. Management will halt guidance and earnings calls as the company pivots to a merger-driven setup.

$TEMHighAI 9/10

Moderna’s Cancer Breakthrough Just Made Tempus AI’s $1.5 Billion Bet Look Brilliant

Tempus AI agreed to acquire Personalis for $1.5B in July 2026. Personalis' tech supports Moderna and Merck's mRNA cancer vaccine, which showed positive Phase 3 results in August 2026. Tempus shares rose 23.91% on the news. Personalis' revenue grew 441.6% YoY in Q2 2026. Tempus reported $382.5M in Q2 2026 revenue, up 22% YoY. The deal is expected to close late Q4 2026 or early 2027.